has also expressed concern based on SCT's close relationship to ADHD, cautioning that a pattern of over-diagnosis of the latter has "already grown to encompass too many children with common youthful behavior, or whose problems are derived not from a neurological disorder but from inadequate sleep, a different learning disability or other sources." Lee states, "The scientist part of me says we need to pursue knowledge, but we know that people will start saying their kids have [sluggish cognitive tempo], and doctors will start diagnosing it and prescribing for it long before we know whether it's real...ADHD has become a public health, societal question, and it's a fair question to ask of SCT." Adding to the controversy are potential conflicts of interest among the condition's proponents, including the funding of prominent SCT researchers' work by the global pharmaceutical company Eli Lilly and, in the case of Dr. Russell Barkley, a leader in the burgeoning SCT research field, direct financial ties to that company (Dr. Barkley has received $118,000 from 2009 to 2012 for consulting and speaking engagements from Eli Lilly). When referring to the "increasing clinical referrals occurring now and more rapidly in the near future driven by increased awareness of the general public in SCT", Dr. Barkley writes "The fact that SCT is not recognized as yet in any official taxonomy of psychiatric disorders will not alter this circumstance given the growing presence of information on SCT at various widely visited internet sites such as YouTube and Wikipedia, among others." See also Attention deficit hyperactivity disorder controversies Bradyphrenia (slowness of thought) Clouding of consciousness Cognitive Tempo Sluggish schizophrenia Type B personality References External links ADHD in Adults: Sluggish cognitive tempo and ADHD Neurological disorders Mental disorders diagnosed in childhood Attention disorders Educational psychology Special education